Dietary iron restriction inhibits progression of diabetic nephropathy in db/db mice

American Journal of Physiology - Renal Physiology

Volumn 304, Issue 7, 2013, Pages

  Ikeda, Yasumasa ^a   Enomoto, Hideaki ^a   Tajima, Soichiro ^a   Izawa Ishizawa, Yuki ^a   Kihira, Yoshitaka ^a   Ishizawa, Keisuke ^a   Tomita, Shuhei ^a,b   Tsuchiya, Koichiro ^a   Tamaki, Toshiaki ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOTTORI UNIVERSITY   (Japan)

Author keywords

Diabetic nephropathy; Iron; NADPH oxidase; Oxidative stress

Indexed keywords

ALBUMIN; FERRITIN; FERROPORTIN; IRON; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; PROTEIN P22; PROTEIN P47; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SUPEROXIDE; TRANSFERRIN RECEPTOR; CYTOCHROME B; NOX4 PROTEIN, MOUSE; P22(PHOX) PROTEIN, MOUSE;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DISEASE COURSE; ENZYME ACTIVITY; ENZYME SYNTHESIS; EXTRACELLULAR MATRIX; FERRITIN BLOOD LEVEL; GLOMERULUS; IRON BLOOD LEVEL; IRON RESTRICTION; KIDNEY PROXIMAL TUBULE; MALE; MESANGIUM CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; URINARY EXCRETION; ALBUMINURIA; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; IRON INTAKE; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ALBUMINURIA; ANIMALS; CYTOCHROME B GROUP; DIABETIC NEPHROPATHIES; IRON, DIETARY; KIDNEY; MALE; MICE; NADPH OXIDASE; OXIDATIVE STRESS;

MLCS; MLOWN;

EID: 84878239025     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00473.2012     Document Type: Article

References (51)

1. Alfrey AC. Toxicity of tubule fluid iron in the nephrotic syndrome. Am J Physiol Renal Fluid Electrolyte Physiol 263: F637-F641, 1992.
2. Ambasta RK, Kumar P, Griendling KK, Schmidt HH, Busse R, Brandes RP. Direct interaction of the novel Nox proteins with p22phox is required for the formation of a functionally active NADPH oxidase. J Biol Chem 279: 45935-45941, 2004.
3. Arosio P, Ingrassia R, Cavadini P. Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta 1790: 589-599, 2009.
4. Asaba K, Tojo A, Onozato ML, Goto A, Quinn MT, Fujita T, Wilcox CS. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 67: 1890-1898, 2005.
5. Cairo G, Recalcati S, Pietrangelo A, Minotti G. The iron regulatory proteins: targets and modulators of free radical reactions and oxidative damage. Free Radic Biol Med 32: 1237-1243, 2002.
6. Camaschella C. Understanding iron homeostasis through genetic analysis of hemochromatosis and related disorders. Blood 106: 3710-3717, 2005.
7. Cooksey RC, Jones D, Gabrielsen S, Huang J, Simcox JA, Luo B, Soesanto Y, Rienhoff H, Abel ED, McClain DA. Dietary iron restriction or iron chelation protects from diabetes and loss of beta-cell function in the obese (ob/ob lep-/-) mouse. Am J Physiol Endocrinol Metab 298: E1236-E1243, 2010.
8. Cuajungco MP, Faget KY, Huang X, Tanzi RE, Bush AI. Metal chelation as a potential therapy for Alzheimer's disease. Ann NY Acad Sci 920: 292-304, 2000.
9. Cutler P. Deferoxamine therapy in high-ferritin diabetes. Diabetes 38: 1207-1210, 1989.
10. Endo K, Miyashita Y, Sasaki H, Ohira M, Saiki A, Koide N, Otsuka M, Oyama T, Takeyoshi M, Ito Y, Shirai K. Probucol delays progression of diabetic nephropathy. Diabetes Res Clin Pract 71: 156-163, 2006.
11. Etoh T, Inoguchi T, Kakimoto M, Sonoda N, Kobayashi K, Kuroda J, Sumimoto H, Nawata H. Increased expression of NAD(P)H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabe-tologia 46: 1428-1437, 2003.
12. Facchini FS, Saylor KL. A low-iron-available, polyphenol-enriched, carbohydrate-restricted diet to slow progression of diabetic nephropathy. Diabetes 52: 1204-1209, 2003.
13. Fernandez-Real JM, Lopez-Bermejo A, Ricart W. Cross-talk between iron metabolism and diabetes. Diabetes 51: 2348-2354, 2002.
14. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Her-nandez-Aguado I, Ricart W. Blood letting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function. Diabetes 51: 1000-1004, 2002.
15. Fleming S. Immunocytochemical localization of ferritin in the kidney and renal tumours. Eur Urol 13: 407-411, 1987.
16. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among US adults. Diabetes Care 22: 1978-1983, 1999.
17. Forouhi NG, Harding AH, Allison M, Sandhu MS, Welch A, Luben R, Bingham S, Khaw KT, Wareham NJ. Elevated serum ferritin levels predict new-onset type 2 diabetes: results from the EPIC-Norfolk prospective study. Diabetologia 50: 949-956, 2007.
18. Geiszt M, Kopp JB, Varnai P, Leto TL. Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA 97: 8010-8014, 2000.
19. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 107: 1058-1070, 2010.
20. Gorin Y, Block K, Hernandez J, Bhandari B, Wagner B, Barnes JL, Abboud HE. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 280: 39616- 39626, 2005.
21. Hayashi H, Takikawa T, Nishimura N, Yano M. Serum aminotransfer-ase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol 22: 268-271, 1995.
22. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 89: 986-988, 1994.
23. Howard RL, Buddington B, Alfrey AC. Urinary albumin, transferrin and iron excretion in diabetic patients. Kidney Int 40: 923-926, 1991.
24. Ikeda Y, Aihara K, Akaike M, Sato T, Ishikawa K, Ise T, Yagi S, Iwase T, Ueda Y, Yoshida S, Azuma H, Walsh K, Tamaki T, Kato S, Matsumoto T. Androgen receptor counteracts Doxorubicin-induced car-diotoxicity in male mice. Mol Endocrinol 24: 1338-1348, 2010.
25. Ikeda Y, Tajima S, Izawa-Ishizawa Y, Kihira Y, Ishizawa K, Tomita S, Tsuchiya K, Tamaki T. Estrogen regulates hepcidin expression via GPR30-BMP6-dependent signaling in hepatocytes. PLos One 7: e40465, 2012.
26. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 291: 711-717, 2004.
27. Koya D, Hayashi K, Kitada M, Kashiwagi A, Kikkawa R, Haneda M. Effects of antioxidants in diabetes-induced oxidative stress in the glom-eruli of diabetic rats. J Am Soc Nephrol 14: S250-253, 2003.
28. Kruszewski M. Labile iron pool: the main determinant of cellular response to oxidative stress. Mutat Res 531: 81-92, 2003.
29. Lau AL, Failla ML. Urinary excretion of zinc, copper and iron in the streptozotocin-diabetic rat. J Nutr 114: 224-233, 1984.
30. Lee DH, Liu DY, Jacobs DR Jr, Shin HR, Song K, Lee IK, Kim B, Hider RC. Common presence of non-transferrin-bound iron among patients with type 2 diabetes. Diabetes Care 29: 1090-1095, 2006.
31. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 14: S241-245, 2003.
32. Li JM, Shah AM. ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J Am Soc Nephrol 14: S221-S226, 2003.
33. Li L, Frei B. Iron chelation inhibits NF-kappaB-mediated adhesion molecule expression by inhibiting p22(phox) protein expression and NADPH oxidase activity. Arterioscler Thromb Vasc Biol 26: 2638-2643, 2006.
34. Li L, Frei B. Prolonged exposure to LPS increases iron, heme, and p22phox levels and NADPH oxidase activity in human aortic endothelial cells: inhibition by desferrioxamine. Arterioscler Thromb Vasc Biol 29: 732-738, 2009.
35. Liu B, Moloney A, Meehan S, Morris K, Thomas SE, Serpell LC, Hider R, Marciniak SJ, Lomas DA, Crowther DC. Iron promotes the toxicity of amyloid beta peptide by impeding its ordered aggregation. J Biol Chem 286: 4248-4256, 2011.
36. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JF, Gerstein HC. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25: 1919-1927, 2002.
37. Makino H, Miyamoto Y, Sawai K, Mori K, Mukoyama M, Nakao K, Yoshimasa Y, Suga S. Altered gene expression related to glomerulogen-esis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes 55: 2747-2756, 2006.
38. Melhem MF, Craven PA, Liachenko J, DeRubertis FR. Alpha-lipoic acid attenuates hyperglycemia and prevents glomerular mesangial matrix expansion in diabetes. J Am Soc Nephrol 13: 108-116, 2002.
39. Minamiyama Y, Takemura S, Kodai S, Shinkawa H, Tsukioka T, Ichikawa H, Naito Y, Yoshikawa T, Okada S. Iron restriction improves type 2 diabetes mellitus in Otsuka Long-Evans Tokushima fatty rats. Am J Physiol Endocrinol Metab 298: E1140-E1149, 2010.
40. Nankivell BJ, Tay YC, Boadle RA, Harris DC. Lysosomal iron accumulation in diabetic nephropathy. Ren Fail 16: 367-381, 1994.
41. Quinn MT, Gauss KA. Structure and regulation of the neutrophil respiratory burst oxidase: comparison with nonphagocyte oxidases. J Leukoc Biol 76: 760-781, 2004.
42. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108: 2154-2169, 2003.
43. Shiose A, Kuroda J, Tsuruya K, Hirai M, Hirakata H, Naito S, Hattori M, Sakaki Y, Sumimoto H. A novel superoxide-producing NAD(P)H oxidase in kidney. J Biol Chem 276: 1417-1423, 2001.
44. Smith MA, Harris PL, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 94: 9866-9868, 1997.
45. Swaminathan S, Fonseca VA, Alam MG, Shah SV. The role of iron in diabetes and its complications. Diabetes Care 30: 1926-1933, 2007.
46. Tajima S, Ikeda Y, Sawada K, Yamano N, Horinouchi Y, Kihira Y, Ishizawa K, Izawa-Ishizawa Y, Kawazoe K, Tomita S, Minakuchi K, Tsuchiya K, Tamaki T. Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice. Am J Physiol Endocrinol Metab 302: E77-E86, 2012.
47. Veuthey T, D'Anna MC, Roque ME. Role of the kidney in iron homeostasis: renal expression of prohepcidin, ferroportin, and DMT1 in anemic mice. Am J Physiol Renal Physiol 295: F1213-F1221, 2008.
48. Ward DT, Hamilton K, Burnand R, Smith CP, Tomlinson DR, Riccardi D. Altered expression of iron transport proteins in streptozoto-cin-induced diabetic rat kidney. Biochim Biophys Acta 1740: 79-84, 2005.
49. Wareing M, Ferguson CJ, Green R, Riccardi D, Smith CP. In vivo characterization of renal iron transport in the anaesthetized rat. J Physiol 524: 581-586, 2000.
50. Yu L, Zhen L, Dinauer MC. Biosynthesis of the phagocyte NADPH oxidase cytochrome b558. Role of heme incorporation and heterodimer formation in maturation and stability of gp91phox and p22phox subunits. J Biol Chem 272: 27288-27294, 1997.
51. Zelle DM, Deetman N, Alkhalaf A, Navis G, Bakker SJ. Support for a protective effect of bilirubin on diabetic nephropathy in humans. Kidney Int 79: 686; author reply 686-687, 2011.